Every therapeutic modality has a distinct development pathway, manufacturing complexity profile, and supplier landscape. Each guide gives pharma and biotech sourcing teams technical depth, supplier selection criteria, regulatory context, and live market intelligence — grounded in the CDMO Hub directory.
Three guides are live. The remaining five are in production — each follows the same 11-section structure, grounded in the directory.
SPPS vs liquid-phase, GLP-1 capacity dynamics, purification & analytical standards across research, clinical, and commercial supply.
74 CDMOs reference peptide capability
Read the guideCell line development through commercial-scale bioreactor production, single-use vs stainless, viral clearance, biosimilar qualification.
79 CDMOs offer monoclonal antibodies
Read the guideAutologous vs allogeneic models, AAV & lentiviral vector production, cell processing, cryopreservation, and capacity planning.
93 CDMOs offer cell & gene therapy
Read the guideAPI process chemistry, HPAPI containment (OEB), oral solid dosage, and multi-site technology transfer.
Recombinant proteins, enzymes, fusion proteins & vaccines — expression-system tradeoffs and GMP readiness.
Plasmid DNA, in-vitro transcription, LNP formulation, and cold-chain sterile fill-finish.
Cytotoxic payloads, linker chemistry, bioconjugation, and DAR characterisation — full-stack vs multi-supplier.
Solid-phase synthesis, phosphorothioate backbones, HPLC/IEX purification, ASO/siRNA/aptamer divergence.
11 sections, the same in every guide: Modality overview · manufacturing workflow & key technologies · development vs. commercial requirements · critical supplier selection criteria · regulatory & quality by region · common challenges & mitigations · global supplier landscape & hubs · capacity trends & outlook · development & scale-up timelines · questions to ask CDMOs · recommended outsourcing strategy by stage.